Why the AMR Industry Alliance?
Antimicrobial resistance poses a formidable threat to the attainment of the Sustainable Development Goals (SDGs).
The United Nations called in 2016 for concerted action from governments and various sectors to address the implications of antimicrobial resistance in a comprehensive manner, and implement strategies at national level.
The AMR Industry Alliance is the life-sciences industry response to the call for action.
Who we are
The AMR Industry Alliance is one of the largest private sector coalitions set up to
provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics,
generics and research-based pharmaceutical companies and associations joining forces.
what we do
We measure and drive the life-sciences industry progress to curb antimicrobial resistance in four different areas:
research & science
Work to reduce the development of antimicrobial resistance
Learn more and for the Appropriate Use Stewardship Prize here.
a broad industry momentum and facilitating collaboration between the public and private sectors.
how we work
Board: The Board is the governing body of the AMR Industry Alliance.
It is responsible for the planning and oversight of AMR Industry Alliance’s activities.
Composition: Biotechs (4) – Diagnostic (4) – Generics (4) – R&D (8) – Associations (4)
Chair of the board: James Anderson, Executive Director, IFPMA
Working Groups dedicated to the 4 action areas: Research & Science, Access, Appropriate Use and Manufacturing
Secretariat: IFPMA serves as the secretariat of the AMR Industry Alliance with the responsibility of implementing the activities endorsed by the Board.